Abstract
Bipolar affective disorder (BD) is a severe, recurrent and disabling disorder with devastating consequences for individuals, families and society. Although these hazards and costs provide a compelling rationale for development of early detection and early intervention strategies in BD, the development of at-risk criteria for first episode mania is still in an early stage of development. In this paper we review the literature with respect to the clinical, neuroantomical and neuropsychological data, which support this goal. We also describe our recently developed bipolar at-risk criteria (BAR). This criteria comprises the peak age range of the first onset of bipolar disorder, genetic risk, presenting with sub-threshold mania, cyclothymic features or depressive symptoms. An initial pilot evaluation of the BAR criteria in 22 subjects indicated conversion rates to proxies of first-episode mania of 23% within 265 days on average, and high specificity and sensitivity of the criteria. If prospective studies confirm the validity of the BAR criteria, then the criteria would have the potential to open up new avenues of research for indicated prevention in BD and might therefore offer opportunities to ameliorate the severity of, or even prevent BD.
Keywords: Bipolar disorder, at-risk criteria, prodrome, conversion, prediction, mania, depression, neuroprogression, psychosis, hallucinations
Current Pharmaceutical Design
Title: Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder
Volume: 18 Issue: 4
Author(s): A. Bechdolf, A. Ratheesh, S. J. Wood, T. Tecic, P. Conus, B. Nelson, S. M. Cotton, A. M. Chanen, G. P. Amminger, S. Ruhrmann, F. Schultze-Lutter, J. Klosterkotter, P. Fusar Poli, A. R. Yung, M. Berk and P. D. McGorry
Affiliation:
Keywords: Bipolar disorder, at-risk criteria, prodrome, conversion, prediction, mania, depression, neuroprogression, psychosis, hallucinations
Abstract: Bipolar affective disorder (BD) is a severe, recurrent and disabling disorder with devastating consequences for individuals, families and society. Although these hazards and costs provide a compelling rationale for development of early detection and early intervention strategies in BD, the development of at-risk criteria for first episode mania is still in an early stage of development. In this paper we review the literature with respect to the clinical, neuroantomical and neuropsychological data, which support this goal. We also describe our recently developed bipolar at-risk criteria (BAR). This criteria comprises the peak age range of the first onset of bipolar disorder, genetic risk, presenting with sub-threshold mania, cyclothymic features or depressive symptoms. An initial pilot evaluation of the BAR criteria in 22 subjects indicated conversion rates to proxies of first-episode mania of 23% within 265 days on average, and high specificity and sensitivity of the criteria. If prospective studies confirm the validity of the BAR criteria, then the criteria would have the potential to open up new avenues of research for indicated prevention in BD and might therefore offer opportunities to ameliorate the severity of, or even prevent BD.
Export Options
About this article
Cite this article as:
Bechdolf A., Ratheesh A., J. Wood S., Tecic T., Conus P., Nelson B., M. Cotton S., M. Chanen A., P. Amminger G., Ruhrmann S., Schultze-Lutter F., Klosterkotter J., Fusar Poli P., R. Yung A., Berk M. and D. McGorry P., Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316226
DOI https://dx.doi.org/10.2174/138161212799316226 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathogenesis of the Left Ventricular Diastolic Dysfunction: The Immune
System Keeps Playing at the Backstage
Endocrine, Metabolic & Immune Disorders - Drug Targets The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Pharmacogenomic Considerations in the Treatment of the Pediatric Cardiomyopathy Called Barth Syndrome
Recent Patents on Biotechnology Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Atrial Tachycardias Arising from the Atrial Appendages and Aortic Sinus of Valsalva
Current Cardiology Reviews Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Transition of Care for Patients with Diabetes
Current Diabetes Reviews Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design FoxO3a Governs Early Microglial Proliferation and Employs Mitochondrial Depolarization with Caspase 3, 8, and 9 Cleavage During Oxidant Induced Apoptosis
Current Neurovascular Research Dose-dependent Effects of PRC2 and HDAC Inhibitors on Cardiomyocyte Hypertrophy Induced by Phenylephrine
Current Drug Targets Cholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome
Current Vascular Pharmacology Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Large Artery Stiffness and Antihypertensive Agents
Current Pharmaceutical Design Direct Antithrombins: New Perspectives in Cardiovascular Medicine
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Efficacy of Zofenopril Alone or in Combination with Hydrochlorothiazide in Patients with Kidney Dysfunction
Current Clinical Pharmacology Natural Plants with Antiepileptic Activity-The Present and Future Perspectives
The Natural Products Journal Effects of Pulmonary Hypertension and Right Ventricular Function in Short and Long-Term Kidney Function
Current Cardiology Reviews Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Genetically Modified Mice as Tools to Understand the Neurobiological Substrates of Depression
Current Pharmaceutical Design